Allergy Therapeutics plc AGY

Ilika (AIM:IKA) says it's now a revenue-generating business, with initial royalties from its Stereax miniature solid-state batteries expected in its 2027 financial year. Releasing its 2026 results, the company said its larger Goliath battery is also attracting interest from defence and e-bike markets, including a collaboration with Brompton Bicycle. Allergy Therapeutics (AIM:AGY) says revenue growth accelerated in its second half, with full-year revenue up 9% to £59.9 million. Double-digit growth is expected next year as Grassmuno enters its first full peak treatment season. Ecora Royalties (L

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season. Second-half revenue is expected to reach £23.6 million,...

Cordiant Digital Infrastructure (LSE:CORD, FRA:86L) has secured two new customer agreements at its Hudson Interxchange data centre in New York, lifting contracted capacity to around 80% of the floor's saleable space. Billing on the first contract starts in September, with full deployment expected by year-end. Helium One Global Ltd (AIM:HE1, FRA:9K3) says its Colorado joint venture has completed its first helium sale under a short-term offtake agreement after its second commercial helium trailer delivery. With regular exchanges now scheduled, the focus is shifting towards recurring sales and ca

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has appointed former HSBC banker Helge Weiner-Trapness as executive chairman as the biotechnology group explores a potential dual primary listing in Hong Kong. Weiner-Trapness, who joined the group as chief strategy officer and an...

The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While antihistamines, corticosteroids, and bronchodilators are frequently used to manage associated symptoms, these agents do not treat anaphylaxis and should only be considered adjunctive therapies alongside epinephrine.

A successful rollout of its newly launched grass-pollen treatment is ste put Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) on the path to self-sustaining profitability. That's according to Cavendish, the AIM-listed biotech's house broker, which cites management's previous commentary...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the immunotherapy company, expects commercial momentum to build through the second half of its financial year as its newly launched Grassmuno grass pollen treatment gains traction in Germany, while planning advances for a phase IIb trial of...

The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed biotechnology company specialising in allergy treatments, said it would present positive clinical and...